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Nitric oxide (NO) plays a critical role in endothelial functions such as cellular migration, vascular 
permeability and angiogenesis. Angiogenesis, the formation of new blood vessels from “pre-existing” 
ones is a carefully regulated process and essential during reproduction, development and wound healing. 
Previously our lab group reported that Secreted Frizzled-Related Protein 4 (sFRP4) could inhibit 
angiogenesis in both in vitro and in vivo conditions. sFRP4 belongs to a family of secreted glycoproteins 
that function as antagonists of the canonical Wnt signalling pathway. Although the pro-apoptotic role of 
sFRP4 is well discussed in literature, little is known in regards to its anti-angiogenic property. The 
objective of this study was to elucidate sFRP4 implications in NO biology of the endothelium. Results 
demonstrate that sFRP4 causes endothelial dysfunction by suppressing NO-cGMP signaling and elevating 
corresponding ROS levels. The imbalance between NO and ROS levels results in apoptosis and 
subsequent leakiness of endothelium as confirmed in vivo (Texas red/Annxin - CAM assay) and in vitro 
(Monolayer permeability assay) conditions. Furthermore utilizing peptides synthesized from the CRD 
domain of sFRP4, our results showed that while these peptides were able to cause endothelial 
dysfunctions, they did not cause apoptosis of the endothelial cells. Thereby confirming that sFRP4 can 
mediate its anti-angiogenic effect independent of its pro-apoptotic property. In conclusion, the current 
study reports that sFRP4-mediated anti-angiogenesis occurs as a result of impaired NO-cGMP signaling 
which in turn allow for elevation of redox levels and promotion of apoptosis of endothelial cells.  















Secreted frizzled-related protein 4 (sFRP4) belongs to a family of secreted glycoproteins that function as 
one of the antagonists of the Wnt signaling pathway [1], which in turn plays an essential role in early 
development, cellular proliferation, migration and angiogenesis [2, 3]. sFRP4 has been reported to play a 
pro-apoptotic role during normal homeostasis of tissues including skin and mammary glands [4-9]. Its 
expression is frequently reported to be down-regulated or deleted in various malignancies resulting in the 
up-regulation of Wnt/β-catenin signaling and excessive cell proliferation [10-16]. Subsequent restoration 
of sFRP4 expression has been shown to not only abrogate Wnt/β-catenin mediated proliferation but also 
promote apoptosis of the cancer cells [10, 11, 17 ]. Furthermore sFRP4 expression has been shown to 
influence chemo-response of cancer cells where low expression is correlated with chemoresistance [18-
20].  
 
We were the first to demonstrate that in addition to its pro-apoptotic and anti-proliferative properties, 
sFRP4 is also a potent angiogenic inhibitor [21], by demonstrating that sFRP4 could inhibit proliferation 
and migration of endothelial cells (EC).  Another important event, which defines angiogenesis, is 
endothelial permeability. It has been shown that the microvasculature is hyperpermeable to plasma 
proteins at the initial phase of angiogenesis. An intact endothelial monolayer demonstrates low-level 
“basal” permeability.  Acute and short-term hyperpermeability, induced by vascular permeability factors 
such as VPF/VEGF-A and other vascular permeabilizing agents, define pro-angiogenic events by cross 
talking with small GTPases, cytokines and adherence junctions [22].  However in regards to the 
mechanism underlying the anti-angiogenic role of sFRP4, our previous studies were only able to hint that 
the anti-angiogenesis effect was mediated indirectly as a consequence sFRP4 suppression of nuclear 
translocation of β-catenin and elevated intracellular reactive oxygen species (ROS) induced apoptotic 
death. A preliminary finding of Muley et al [21] was that administration of exogenous VEGF was unable 
to blunt sFRP4 mediated effects, however the effect of sFRP4 on the downstream nitric oxide (NO) 
pathway remains unknown.  Considering that an increase in ROS production and the corresponding 
inactivation of NO has been shown to cause endothelial dysfunction [23], we hypothesized that sFRP4 
interferes with endothelial permeability via NO/sGC/cGMP pathway and thereby perturbs angiogenesis. 
 
The present study elaborated that ectopic dosage of sFRP4 induces oxidative stress in endothelium and 
simultaneously attenuates NO production. This imbalance in redox status of endothelium promotes 
apoptosis; and facilitates para-cellular gap formation in endothelium. The endothelial monolayer with 





2. Materials and Methods 
2.1. Materials 
DMEM (Dulbecco’s modified Eagle’s medium) was purchased from PAN-Biotech GmbH. FBS (Fetal 
bovine serum) was purchased from Invitrogen Life Technologies. Spermine NONOate (SP) and 
guanosine-3’ 5’-monophosphate 8-bromo-sodiumsalt (8-Br) were purchased from EMD Biosciences, Inc., 
California, USA. Diaminorhodamine (DAR-4M-AM),  sildenafil citrate (SC), 3-(5-hydroxymethyl-2-
furyl)-1-benzyl indazole  (YC-1), vascular endothelial growth factor (VEGF), L-NAME, Amplex Red and 
Catalase (CAT) from bovine liver were obtained from Sigma Chemical  Co., St. Louis. Phalloidin-Alexa 
Fluor 568 (Phalloidin), DAR-4M AM, diamino-fluorescein (DAF-FM),  2’, 7’-dichlorofluorescein 
diacetate (DCF-2DA) and  Dihydrorhodamine 123 (DHR) was purchased from Molecular probe, 
Oregon,USA. sFRP4 protein was purchased from Sino Biological Inc. sFRP4 CRD peptides were 
obtained from Imgenex India Pvt. Ltd. Bhubaneshwar, India. Cadmium chloride (CdCl2) was purchased 
from Hi-Media, Mumbai, India. All other chemicals were of reagent grade and were obtained 
commercially.  
2.2. Cell Lines 
Immortalized endothelial hybrid cell lines, EAhy926 and ECV304 cells stably transfected with eNOS-
GFP constructs (kind gifts from Dr. C.J.S Edgell and Dr. Vijay Shah, Mayo Clinic Rochester USA) and 
primary dermal microvascular endothelial cells (HDMVEC; from ATCC, USA) were cultured in DMEM 
supplemented with 10% FBS and 1% penicillin-streptomycin. 
2.3 Estimation of Nitric oxide (NO):  
2.3.1. Griess assay: NO was measured using Griess protocol as previously described [24]. Griess assays 
were performed on EAhy926 cells to determine optimal dosage (125, 250 and 500 pg/ml) and duration 
(30 min, 1, 3, 6, 12 and 24 h) of sFRP4 treatments.  The Griess assay was also performed on freshly 
slaughtered bovine aortas obtained from government authorized abattoir. Briefly, bovine aortas were 
washed with 1 X PBS and then cut into ring like structures. Aortic rings were then placed in sterile 12-
well petri-plate and incubated with PBS containing either sFRP4, positive control L-Arginine (L-Arg) or 
negative control L-NAME for 4 h. The solution was then carefully collected and measured. 
2.3.2. NO measurement using DAF-2DA: DAF-2DA was performed on HDMVEC and EAhy926 cells 
following treatment with 250 pg/ml sFRP4 for 4 h as per the protocol described elsewhere [25].  
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2.3.3. DAF-FM fluorimetric assay: DAF-FM was performed on EAhy926 cells treated with sFRP4 (250 
pg/ml), Bradykinin (BK; 5 μM), SP (10 μM), 8-Br (50 μM), CAT (30 U), MnTBAP (10 μM) and their 
combinations with sFRP4 for 4 h as per the protocol described elsewhere [26]. L-Arg was used as 
positive control. DAF-FM were also performed for sFRP4 CRD domain peptides (CP-128-10, CP-129-
10, CP-130-10, CP-131-10, CP-132-10, CP-133-10, CP-134-10). 
2.3.4. DAR-4M-AM live cell imaging:  ECV304 stably transfected with eNOS-GFP were then grown 
overnight as monolayers on coverslips. The monolayers were treated with sFRP4 for 4 h. Following 
treatment the monolayers were washed with 1X PBS and then incubated with NO-specific fluorescence 
probe DAR-4M-AM for 10 min. The monolayer was washed again with 1X PBS before corresponding 
bright field and fluorescence images were taken at 20X magnification using an Olympus fluorescence 
microscope. The fluorescence intensity of eNOS and DAR were calculated using Adobe Photoshop 
version 7.0 software program.  
2.4. Fluorescence live cell imaging: ECV304 stably transfected with eNOS-GFP cells were grown 
overnight at 40% confluency on coverslips in 12-well plates. The cells were treated with control, sFRP4,  
BK and sFRP4 + BK respectively. Following treatment, cells were placed in live-cell chambers and 
eNOS localization was observed using an Olympus IX71 epifluorescence microscopy system equipped 
209 with a DP71 camera. 
2.5 Phallodian staining: EAhy926 monolayers and single cell plated on coverslips were treated with 
sFRP4 for 4 h before being stained with phallodian as per the protocol described elsewhere [27]. 
2.6 Permeability assays 
The term 'leakiness' denotes net permeability and is inclusive of both para-cellular and trans-cellular 
vascular solute fluxes [27].  
2.6.1 Texas Red monolayer permeability:  Endothelial monolayer leakiness was assessed as previously 
described [27], with minor modifications (Figure 1 C). Briefly, EAhy926 monolayers were grown 
overnight on collagen-coated polycarbonate membranes in permeability chambers. Monolayers were 
treated with sFRP4, SP, 8-Br, CAT, MnTBAP and their combinations with sFRP4 for 4 h.  Following 
treatment, the monolayers were gently washed with 1X PBS and then incubated with 10 μM Texas red for 
1 h. The solution from the lower chamber was then collected and measured using a Varian Cary Eclipse 
UV–Vis Fluorescence spectrophotometer at excitation/emission of 589/615 nm. Texas red monolayer 
permeability assays were also performed following treatment with sFRP4 CRD domain peptides CP-133-
10 and CP-134-10. 
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2.6.2. Texas red permeability assay in Chorionic-Allantoic Membrane (CAM): Fertilized four day 
incubated eggs were obtained from Poultry Research Station, Potheri, Chennai. Texas red permeability 
assays were performed on CAM treated with control (1X PBS), sFRP4 , SP and sFRP4 + SP for 4 h as per 
protocol described elsewhere [26].   
2.6.3. CdCl2 Texas red curve: A Texas Red-Cadmium scale was generated by treating EC monolayers 
and CAMs to increasing doses of CdCl2 (0-100 μM/ml) for 2 h.  
2.7. Transfections: EAhy926 cells grown in 24-well plates were transfected with FlincG plasmid 
(addgene-pcDNA3.1 (+)-deltaFlincG) encoding PKG–GFP as per the protocol described previously [25]. 
40 h post transfection, cells were treated with sFRP4 and negative control cPTIO for 4 h. Images were 
taken using an Olympus IX71 fluorescence microscope and the fluorescence intensity was calculated 
using the Adobe Photoshop version 7.0 software programe. 
2.8. Endothelial scratch-wound assay: The scratch-wound assay was performed on EAhy926 
monolayers treated with sFRP4, YC-1, SC and 8-Br and their combinations as previously described [25]. 
Images of the wound area were taken 0, 2 and 4 hours using a Nikon digital camera and the area of the 
cell-free wound at 2 and 4 h time points was analyzed using Image J image software. 
2.9. Western blot analysis: EAhy926 cells were treated with sFRP4 for 4 h. Triton X soluble and 
insoluble fractions were prepared as per protocol described elsewhere [23] and western blots were 
performed for eNOS protein expression (1:1000 dilution, SC-654, 199 Santa Cruz, CA, USA).  
2.10. Estimation of reactive oxygen species (ROS): Four parameters were assessed including total ROS, 
superoxide, peroxynitrite, and hydrogen peroxide (H2O2) production in EAhy926 endothelial cells 
following respective treatments. 
2.10.1. Total ROS assay: In first experiment, cells were treated with sFRP4 doses in the presence and 
absence of superoxide dismutase (SOD) (150 SI Units). In the second experiment cells were treated with 
sFRP4, SP, 8-Br, CAT, MnTBAP and their respective combinations. Total ROS levels were measured 
using fluorescent probe DCF-DA as per the protocol described elsewhere [21].  
2.10.2. Amplex red assay: Cells were treated with sFRP4, SP, 8-Br, CAT, MnTBAP and their 
combinations for 4 h. The Amplex red assay was performed as per protocol previously described [21]. 
2.10.3. Measurement of peroxynitrite:  Following treatment with sFRP4, SP, 8-Br, CAT, MnTBAP and 




2.10.4. Nitro Blue Tetrazolium (NBT) Assay: Following treatment with sFRP4, SP, 8-Br, CAT, 
MnTBAP and their combinations for 4 h, the NBT assay was performed as per protocol described 
previously [21]. 
 
2.11. Measurement of Annexin-Propidium iodide staining: Apoptosis was detected in EAhy926 cells 
and CAM with help of Annexin-propidium iodide (PI) staining (Calbiochem PF032). EC were subjected 
to treatment with sFRP4, SP, 8-Br, CAT, MnTBAP and their combinations for 4 h. Staurosporine (STP) 
was used as positive control. After treatment, the cells were then washed three times with 1 X PBS and 
then incubated with binding buffer, Annexin V and PI, respectively, as per the manufacture’s protocol. 
Fluorescent images of Annexin and PI were captured using Olympus XL70 fluorescent microscope. The 
fluorescence intensity of the images was quantified using Adobe Photoshop version 7.0. Annexin-PI 
staining was also performed on EC following treatment with sFRP4 CRD domain peptides CP-133-10 
and CP-134-10. 
 
The same protocol was applied for CAM following treatment with sFRP4, SP and their combination, 
albeit with minor modification. Briefly, following treatment, CAM were washed with 1X PBS and 
incubated with Texas red dye for 30 min. The CAM were again washed with 1X PBS and incubated with 
Annexin V + binding buffer alone. The CAM were then fixed with 4% paraformaldehyde for 10 min 
before images in bright field, green (Annexin V) and red (Texas Red) fluorescence were taken using an 
Olumpus IX71 epifluorescence microscope equipped with a DP71 camera.   
 
2.12. Statistical analysis: All experiments were performed in triplicate (n=3) unless specified otherwise. 
Data are presented as mean ± SE. Data was analyzed using one-way analysis of variance (ANOVA), 
student’s t test, and Turkey’s post hoc tests using the SIGMA STAT software package version 4. p<0.005 
was considered to be statistically significant.  
 
3. Results 
3.1. sFRP4 induced leakiness of endothelium 
The accumulation of Texas Red dye within CAM blood vessels is indicative of vessel leakiness. Analysis 
of Texas Red permeability assays performed on CAM showed that sFRP4 treatment (250 pg/ml) induced 
significant accumulation of dye within blood vessels when compared to control vessels (p<0.001) (Figure 
1A and B).  Furthermore sFRP4 demonstrated a dose dependent effect on EC leakiness in vitro, with both 
the 250 and 500 pg/ml doses of sFRP4 inducing significant dye permeation (p<0.001) past the EC 
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monolayer in comparison to control monolayers (Figure 1D). As both doses yielded similar results, we 
elected to use 250 pg/ml as our treatment dose for subsequent experiments. Although the 125 pg/ml dose 
of sFRP4 also showed increased dye permeation into the lower chamber of the permeability chamber 
apparatus, this finding was not significant.  In order to estimate the extent of sFRP4 mediated endothelial 
leakiness in both in vivo (CAM) and in vitro (EC monolayer) conditions, we plotted our results on a 
Texas Red-Cadmium scale. Cadmium is a well known teratogen that causes endothelial leakiness [29, 
30]. The Texas Red-Cadmium scale was generated by subjecting CAM and EC monolayers to increasing 
concentrations of CdCl2 thereby resulting in an increasing scale of dye permeation. When plotted on the 
Cadmium scale, results demonstrated that 250 pg/ml dose of sFRP4 induced endothelial leakiness that 
was comparable to 5 μM CdCl2 (Figures 1E and F). Assessment of cytoskeleton arrangements of EC 
using phallodin staining showed formation of large gaps in the EC monolayers following sFRP4 
treatment which were absent in control monolayers (Figure 1G – monolayer). Furthermore phallodin 
staining of single cells revealed that the sFRP4 treated cells demonstrated diffused and diminished actin 
distribution instead of the rigid and even actin distribution observed in control cells (Figure 1G – single 
cells; Supplementary Figure 1A). 
3.2. sFRP4 attenuates NO-cGMP signaling in endothelial cells  
To determine if sFRP4 inhibition of endothelial function occurred via suppression of NO pathway, Griess 
and DAF-FM assays were first used to assess the dose dependent effect of sFRP4 on NO production of 
EC. L-Arg a  precursor of NO was used as positive control. Results showed that all three doses of sFRP4 
(125, 250 and 500 pg/ml) significantly decreased NO production of EC, when compared to control cells, 
(Figure 2A). Furthermore, a time dependent study showed that 250 pg/ml of sFRP4 began inhibiting 
endothelial NO production around 3 h post treatment and continued to significantly inhibit NO production 
for 24 h (Figure 2B). Next using DAF-2DA imaging, we compared the effects of sFRP4 on NO 
production between an immortalized hybrid endothelial cell line EAhy926and a primary endothelial cell 
line HDMVEC. Results showed that sFRP4 significantly decreased NO production EC irrespective of cell 
origin (Figure 2C). Additionally sFRP4 also significantly (p<0.001) decreased NO production of 
endothelial cells lining freshly dissected bovine aortic rings (Figure 2D).  
 
We then investigated the effects of sFRP4 on eNOS localization with the help of ECV304 cells that were 
stably transfected with eNOS-GFP. Results showed that treatment with sFRP4 induced extensive eNOS 
re-localization from nuclear membrane towards plasma membrane of the cells (depicted with white 
arrows) in sFRP4 treated cells, compared to control and BK treated cells (Figure 3A). Interestingly 
subsequent addition of BK to sFRP4 treated cells was able to partially restore eNOS localization to the 
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nuclear membrane from the plasma membrane (depicted with yellow arrows) (Figure 3A). Western blot 
analysis of eNOS in triton-soluble and triton-insoluble fractions, showed increased eNOS in triton-
insoluble fractions in sFRP4 treated cells when compared to control cells (Figure 3B), hinting that sFRP4 
inhibition of NO could be occurring via the sGC-cGMP signaling pathway. 
 
To establish that sFRP4 has a direct effect on downstream NO-cGMP signaling, we demonstrated that on 
sFRP4 treatment of FlincG (a PKG-GFP construct) transfected EC significantly decreased cellular cGMP 
level when compared to control transfected cells (p<0.001) (Figures 3C). Interestingly the sFRP4 induced 
effects were similar to the effect of the negative control cPTIO (a NO specific quencher). Scratch-wound 
assays showed that addition of activators of sGC-cGMP signaling like YC-1, SC were able to alleviate 
sFRP4 mediated inhibition of wound healing, with cGMP analog 8-Br demonstrating significant recovery 
compared to sFRP4 treated cells (Figure 4A). Furthermore supplementation of NO either via 8-Br or SP 
was able to significantly blunt sFRP4 effects and restore NO production of treated cells (p<0.001) (Figure 
4B). Taken together results confirm that sFRP4 inhibition of NOS attenuates cGMP production and 
therefore dampens cGMP-PKG signalling in endothelial cells.  
3.3. Rescuing endothelial cells from sFRP4 mediated effect by reducing ROS levels  
In the current study we have demonstrated that 250 pg/ml sFRP4 significantly elevated the hydrogen 
peroxide, peroxynitrite and total ROS levels of EC (Supplementary Figure 1 B and C), while addition of 
anti-oxidant SOD was able to significantly decrease total ROS levels of these cells. Although addition of 
both CAT (an enzyme that activates hydrogen peroxide degradation) and MnTBAP (SOD) to sFRP4 
treated EC demonstrated increased NO levels, this finding was not significant (Figure 4C). Subsequent 
addition of either antioxidants or NO donors (SP) or cGMP analog 8-Br significantly decreased redox 
levels (total ROS, hydrogen peroxide, peoxynitrite and superoxide) of sFRP4 treated EC when compared 
to cells treated with only sFRP4 (Figure 5). Elevated ROS levels are associated with increased apoptosis. 
Accordingly, Annexin/PI staining of EC showed significantly increased annexin positive cells, indicative 
of apoptosis. In contrast, administration of NO or negating ROS levels was found to rescue the cells from 
apoptosis (Figure 6; Supplementary Figure 1 D). 
 
3.4. sFRP4 mediates its anti-angiogenic effect by dampening NO-cGMP signalling  
In the current study we demonstrate that sFRP4 directly dampens NO production in EC. To determine if 
decreased NO production, rather than elevated ROS/apoptosis, was responsible for the anti-angiogenic 
effects of sFRP4, we performed the following three separate experiments.  
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In the first experiment, we assessed real time NO production and cell morphology of stably transfected 
ECV304 cells following treatment with sFRP4. eNOS expression (green) and NO diffusion from the cells 
(red) was recorded for both control and sFRP4 treated monolayer (Figure 7A). Control monolayers 
exhibited a greater proportion of eNOS expressing cells, larger distribution of diffused NO, as indicative 
of DAR-4M-AM florescence, and structurally robust cells with no gaps (Figure 7B). Additionally merged 
images of eNOS and DAR-4M-AM images showed significantly higher number of yellow cells. In 
contrast sFRP4 treated monolayers showed significantly decreased eNOS expression and consequently 
reduced NO diffusion (p<0.001) (Figure 7C). Similarly merging of images revealed very a weak 
proportion of yellow cells. The most significant observation was that the decreased NO production 
seemed to directly correlate with an increased number of gaps in the EC monolayer.  
In the second experiment, we co-performed Texas red and Annexin staining on sFRP4 treated CAM 
blood vessels. Interestingly results showed that areas demonstrating increased Texas red accumulation 
within the blood vessels following sFRP4 treatment also showed increased apoptosis when compared to 
control and SP treated CAMs. Subsequent addition of the NO donor SP to sFRP4 treated CAMs was able 
to significantly curtail the amount of dye permeating into the vessel despite not being able to completely 
inhibit apoptosis (Figure 8 A-C). Further analysis of in vitro permeability assays revealed that restoration 
of NO levels using either SP or 8-Br was able to significantly decrease gap formation of sFRP4 treated 
EC monolayers. Whereas neutralization of ROS levels by anti-oxidants (CAT/MnTBAP) were not able to 
prevent sFRP4 mediated leakiness of the EC monolayer (Figure 8D). 
Finally with the help of synthesized peptides of the CRD domain of sFRP4, we determined if sFRP4 
could mediate its anti-angiogenic role independent of its pro-apoptotic effect.  Of the seven peptides 
available, we identified peptides CP-131-10, CP-133-10, CP-134-10 were able to significantly decrease 
NO production in EC cells (Figure 9A). While both peptide CP-133-10 and CP-134-10 were able to cause 
significant leakiness of the EC monolayer (albeit to a lesser degree than whole sFRP4 protein) compared 
to control cells; neither peptide demonstrated any significant increase in apoptosis (Figure 9 B-D).  Taken 
together these findings confirm that sFRP4 can mediate its anti-angiogenic effect via inhibition of NO 
signaling and endothelial dysregulation in addition to its ROS-induced apoptosis. We also confirm that 
sFRP4 can implement its anti-angiogenic effect independent of its pro-apoptotic role.  
4. Discussion  
 
The discovery of sFRP4 anti-angiogenic properties was particularly profound. sFRP4 mimicked the 
efficacy demonstrated by the clinically approved angiogenesis inhibitor, Avastin (a VEGF-blocking 
antibody) in inhibiting angiogenesis of aggressive ovarian tumors implanted in BALB/c  nude mice [21]. 
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A limitation of this study was that the combined effect of sFRP4 and Avastin was not explored, however 
preliminary in vitro data showed that exogenous VEGF was unable to negate sFRP4's inhibitory effects. 
Consequently, in part due to the finding that apoptotic activity in these tumors was localized to 
endothelial regions, it was postulated that the anti-angiogenic property of sFRP4 possibly occurred as an 
indirect consequence of its anti-proliferative and pro-apoptotic effects. The present study made an effort 
to understand the link between the anti-angiogenesis and pro-apoptotic effects of sFRP4 on endothelial 
cells. 
 
Sinha et al [31] highlighted the role played by NO/sGC/cGMP pathway during endothelial ring formation, 
a crucial angiogenic step. Interestingly studies demonstrating the failure of VEGF in inducing 
angiogenesis in eNOS-/- mice, indicate that NO is the critical mediator of VEGF induced angiogenesis 
[32, 33]. Maintenance of the endothelium and the regulation of vascular permeability is also a key 
function of the NO/cGMP pathway [27, 33, 34]. Considering the importance of NO in endothelial 
biology, we postulated that sFRP4 mediates its anti-angiogenic ability via direct inhibition of NO within 
the endothelial cell, disrupting NO signaling, which causes subsequent endothelial dysfunction and 
leakiness of the endothelium. Preliminary results indicate that sFRP4 treatment increased endothelial 
leakiness in both in vitro and in vivo conditions. We were able to attribute sFRP4 induced endothelial 
leakiness to the formation of gaps resulting from sFRP4 mediated reorganization of the EC cytoskeleton. 
Furthermore, using live cell imaging, we were able to positively correlate sFRP4 mediated attenuation of 
endogenous NO production and the subsequent formation of gaps in the endothelial monolayer. Results 
also demonstrated that sFRP4 decreased NO production in EC irrespective of cell origin (micro- vs. 
macro-vascular EC) and that this inhibition remained effective up to 24 h post treatment. Our data 
parallels previous studies that have similarly shown altered endothelial actin cytoskeleton and increased 
vascular permeability following inhibition of NO synthesis [26, 27, 35].  
 
The management of eNOS sub-cellular localization is key to the proper facilitation of NO production, 
while its mislocalization impairs angiogenesis [36, 37]. Live cell imaging revealed that sFRP4 prevented 
the peri-nuclear localization of eNOS. This was further confirmed by immunoblot analysis which showed 
that sFRP4 treatment increased eNOS content in the triton-insoluble fraction, a known abode for caveolin, 
a chronic inhibitor of eNOS activity.  Based on these results we postulated that sFRP4 modulates the sub-
cellular localization of eNOS to blunt NO production and endothelial permeability.  Recently Perumal et 
al [39] reported that sFRP4 induced cell death via its inhibition of Akt survival pathways. Considering 
that direct phosphorylation of eNOS by Akt is one of the methods via which VEGF facilitates the 
activation of eNOS, it is quite plausible that sFRP4 can target eNOS both directly as well as indirectly, 
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which also explains why exogenous VEGF was ineffective against sFRP4. To further dissect sFRP4 
inhibition of NO signaling, we next probed the NO/sGC/cGMP pathway. NO once released binds to sGC 
to produce cGMP [39-42]. To directly assess the effect of sFRP4 on cGMP signaling, we transfected 
EAhy926 cells with a PKG-GFP construct (FlincG) prior to treatment with sFRP4. Results demonstrated 
that sFRP4 significantly suppressed cellular cGMP level, suggesting that sFRP4 induces endothelial 
leakiness in a sGC-cGMP dependent manner.  
 
Omori & Kotera et al [43] demonstrated that the inhibition of in vitro tube formation in eNOS-/- mice 
could be restored via addition of a NO donor. While Antonova et al [44] reported that preconditioning 
with low doses of a NO donor could accelerate the repair and maintenance of endothelial integrity via the 
sGC pathway. Previous reports from our lab group have also shown that treatment with NO donors or 
cGMP analogs can restore and protect endothelial function, morphology and barrier integrity [26, 27, 45-
47]. Similarly, we noted that addition of NO donor SP or activators of NO/sGC/cGMP activity such as 
YC-1 (an NO independent activator of sGC), SC (which increases cellular cGMP by PDE inhibition) and 
8-Br (cGMP analogue) could blunt sFRP4 mediated effects.  Previously we have shown that endothelial 
dysfunction, whether hypoxia-driven or induced by teratogens  (cadmium, thalidomide), occurs primarily 
as a consequence of decreased intercellular NO bioavailability and/or bioactivity and elevated ROS 
levels, which promotes apoptosis [26, 27, 45-47]. Superoxide production in EC has been reported to 
contribute to enhanced permeability of EC membrane [48], particularly as NO is known for its strong 
affinity to react with superoxide radicals [49] to form peroxynitirite and thereby causing leakiness of the 
endothelium. Alternatively pretreatment of cells with NO donors has been shown to increase endothelial 
cGMP activity and suppress hydrogen peroxide-related effects on permeability [50]. Similarly, addition of 
both the NO donor, SP and the cGMP analog, 8-Br were effective in both suppressing ROS levels and 
preventing apoptosis in sFRP4 treated cells. Furthermore, we observed that both SP/8-Br cGMP 
treatments were able to blunt sFRP4 mediated effects (NO dampening, elevation of ROS/apoptosis) with 
greater efficacy when compared to  antioxidant treatment.  
 
In vivo co-localization of annexin and texas red staining revealed that sFRP4 mediated its anti-angiogenic 
effects by both inhibition of NO signaling as well as causing apoptosis of the affected cells. Intriguingly, 
addition of SP to sFRP4 treated CAMs was able to significantly restore endothelial function and decrease 
the permeability of these vessels, despite not having completely inhibited apoptosis of these cells. This 
evidence, coupled with the ineffectiveness of antioxidants to blunt sFRP4 mediated leakiness of the EC 
monolayer, indicates that the restoration of NO, rather than the neutralization of ROS, attenuates 
leakiness of the endothelium. This finding also raised the question whether the anti-angiogenic and pro-
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apoptotic roles of sFRP4 could function independent of one another. We tested this theory by studying the 
effects of peptides synthesized from the sFRP4 CRD domain, which has been previously reported by 
Longman et al [51] to be the domain responsible for sFRP4’s anti-angiogenic affect. Results showed that 
while peptides 6 and 7 were able to decrease NO production and cause significant leakiness of the EC 
monolayer, they did not induce these cells to undergo apoptosis like the total protein, sFRP4 could.   
 
The present study reveals that sFRP4 mediates its anti-angiogenic effects, in part, via the direct inhibition 
of the NO/cGMP signaling pathway, resulting in endothelial dysregulation. Furthermore this study also 
demonstrates that the anti-angiogenic and pro-apoptotic roles of this protein can target endothelial cells 
simultaneously. More importantly, sFRP4 appears to induce apoptosis in the endothelium via cGMP 
inhibition, and the manifestation of apoptosis in the endothelium is initially leakiness of the monolayer 
followed by disruption of vascular structures. In conclusion, sFRP4 uses two distinct pathways in the 
endothelium; pro-apoptotic and anti-angiogenesis, by dampening the NO-cGMP-permeability cascade in 
endothelial cells.   
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Figure 1. sFRP4 induces leakiness of the Endothelium. (A) Representative corresponding bright field and 
Texas red images of control and sFRP4 treated CAM. (B) Quantification of permeated dye intensity in 
control and 250 pg/mlsFRP4 treated CAM. n=4; *p<0.001, vs. control. (C) Schematic representation of 
Texas red permeability assays performed in vitro on EC monolayers. (D) Graphical representation of 
Texas red permeability assay performed on EC monolayers following treatment with 125, 250 and 500 
pg/ml doses of sFRP4. n=3; *p<0.001, vs. control. Plotting of 250 pg/ml sFRP4 treatment induced dye 
permeation on Texas Red-Cadmium scale in CAM (E) and endothelial monolayers (F) equivalent to 5 μM 
CdCl2. (G) Representative images of phallodin stained monolayers and single cells in control and sFRP4 
treated cells. Values represent the mean for each group, obtained from 3 independent experiments ± SEM 
(one way ANOVA and LSD).  
 
Figure 2. sFRP4 dampens NO production of EC. (A) Graph representing estimated NO levels of EC 
subjected to 125, 250 and 500 pg/ml doses of sFRP4. n=6; *p<0.01, vs. control; **p<0.001, vs. control. 
(B) Time-dependent study demonstrated that 250 pg/ml sFRP4 suppressed NO production from 3 h upto 
24 h post treatment. n=6; †P<0.002, 6h sFRP4 vs. control; *p<0.01, 12h sFRP4 vs. control; **p<0.001, 
24h sFRP4 vs. control. (C) Representative corresponding bright field and DAF-2DA images of control 
and sFRP4 treated HDMVEC and EAhy926 cells. (D) Graphical representation of DAF-2DA 
fluorescence intensity calculated. n=4; ††P<0.003, vs. control; **p<0.001, vs. control. (E) Graphical 
representation of NO production quantified for bovine aortic cells following treatment. n=3; **p<0.001, 
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vs. control. Values represent the mean for each group, obtained from 3 independent experiments ± SEM 
(one way ANOVA and LSD).  
 
Figure 3. sFRP4 blunts NO in cGMP dependent manner. (A) Representative images of eNOS localization 
of ECV304 cells stably transfected with eNOS-GFP following treatment with (i) control, (ii) BK, (iii) 
sFRP4 and (iv) sFRP4 + BK.  (B) Graphical representation of the number of cells demonstrating eNOS 
localization. (C) Western blot of triton-soluble and insoluble proteins probed for eNOS in control (c) and 
sFRP4 (s4) treated EAhy926 cells.  (D) Representative corresponding bright field and FlincG transfected 
EAhy926 cells following treatment with control, negative control cPTIO and sFRP4. (E) Graphical 
representation of FlincG fluorescence intensity calculated following treatments. n=4; **p<0.001, vs. 
control.  Values represent the mean for each group± SEM (one way ANOVA and LSD).  
 
Figure 4. (A) Graphical representation of 2 and 4 h scratch-wound healing results following treatment 
with control, sFRP4, YC1, SC, 8-Br and combinations. n=4; #p<0.04, 2h sFRP4 + 8-Br vs. sFRP4; 
*p<0.01, 4h sFRP4 + 8-Br vs. sFRP4. (B) Addition of SP and 8-Br alleviated sFRP4 mediated 
suppression of NO production. n=6; **p<0.001, vs. sFRP4.  (C) Estimation of NO production following 
addition of anti-oxidants CAT and MnTBAP respectively to sFRP4 treated cells. Values represent the 
mean for each group± SEM (one way ANOVA and LSD).  
 
Figure 5. Supplementation of NO or neutralization of redox levels rescued EC from sFRP4 induced 
oxidative stress. Graphs represent endothelial ROS levels evaluated following treatment with control, 
sFRP4, SP, 8-Br, CAT, MnTBAP and their combinations. n=6. (A) Total ROS levels quantitated 
following treatment of EC. †P<0.006, **p<0.001, *p<0.01; vs. sFRP4. (B) Hydrogen peroxide levels 
quantitated for EC following treatment. **p<0.001, *p<0.01, # p<0.02, vs. sFRP4. (C) Superoxide levels 
quantitated following treatment. **p<0.001, *p<0.01, vs. sFRP4. (D) Peroxynitrite levels quantitated 
following treatment. **p<0.001, *p<0.01, vs. sFRP4. Values represent the mean for each group± SEM 
(one way ANOVA and LSD).  
 
Figure 6. Supplementation of NO or neutralization of redox levels rescued EC from sFRP4 induced 
apoptosis. (A) Representative images of corresponding bright field, Annexin V, and PI of endothelial 
cells following treatment with control, sFRP4, SP, 8-Br, CAT, MnTBAP and their combinations. 
Staurosporine (STP) was used as positive control. (B) Graphical representation of the intensity of 
Annexin V and PI fluorescence calculated. n=6; **p<0.001, *p<0.01, vs. sFRP4 - Annexin V. †p<0.01, # 




Figure 7. (A) Representative corresponding bright field, eNOS, DAR-4M-AM and merged images of 
control and sFRP4 treated ECV304 stably transfected with eNOS-GFP monolayers. Black arrows indicate 
formations of gaps in EC monolayer. (B) Graph comparing the cell clusters demonstrating green (eNOS), 
red (DAR-4M-AM), yellow (merged) and black (gaps) in control and sFRP4 treated cells. (C) Graphs 
representing the fluorescence intensity calculated for eNOS and DAR-4M-AM in control and sFRP4 
treated monolayers. **p<0.001, vs. control - eNOS; †p<0.001, vs. control - DAR-4M-AM. Values 
represent the mean for each group± SEM (one way ANOVA and LSD). 
 
Figure 8. (A) Representative corresponding bright field, Texas red, Annexin V and merged images of 
control, sFRP4, SP and sFRP4 + SP treated CAM. (B) Graph representing the Texas red and Annexin V 
fluorescence intensity calculated. **p<0.001, vs. control - Texas red; †p<0.001, vs. control - Annexin V. 
(C)  Quantification of permeated texas red dye intensity in control, sFRP4, SP and sFRP4 + SP treated 
CAM. **p<0.001, vs. sFRP4. (D) Graphical representation of Texas red permeability assay performed on 
EC monolayers following treatment with control, sFRP4, SP, 8-Br, CAT, MnTBAP and their 
combinations. ††p<0.002, *p<0.01 vs. sFRP4. Values represent the mean for each group± SEM (one way 
ANOVA and LSD).  
 
Figure 9. (A) Graph representing the estimated NO levels of EC subjected control, sFRP4 and sFRP4 
CRD domain peptides. †p<0.002, **p<0.001, vs. control. (B) Quantification of permeated texas red dye 
intensity in control, sFRP4 and sFRP4 CRD peptides (CP-133-10 and CP-134-10). #p<0.005, 
**p<0.001,vs control. (C) Representative images of corresponding bright field, Annexin V, PI stained 
cells following treatment with CP-133-10 and CP-134-10. (D) Graphical representation of the intensity of 
Annexin V and PI fluorescence calculated. n=6. Values represent the mean for each group± SEM (one 
way ANOVA and LSD).  
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